COVID‐19‐related neuropathology and microglial activation in elderly with and without dementia. (18th June 2021)

• Record Type: Journal Article
• Authors: Poloni, Tino Emanuele; Medici, Valentina; Moretti, Matteo; Visonà, Silvia Damiana; Cirrincione, Alice; Carlos, Arenn Faye; Davin, Annalisa; Gagliardi, Stella; Pansarasa, Orietta; Cereda, Cristina; Tronconi, Livio; Guaita, Antonio; Ceroni, Mauro
• Is Part Of: Brain pathology. Volume 31:Number 5(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-06-18
• Subjects: COVID‐19 -- dementia -- elderly -- microglia -- neurocognitive disorders -- neuropathology; Nervous system -- Diseases -- Periodicals; Brain -- Diseases -- Periodicals; Neurology -- Periodicals; Brain Diseases -- Periodicals; Cerveau -- Maladies -- Périodiques; Système nerveux -- Maladies -- Périodiques; Neurologie -- Périodiques; 616.805
• DOI: 10.1111/bpa.12997
• Languages: English
• ISSNs: 1015-6305

Abstract

Abstract: The actual role of SARS‐CoV‐2 in brain damage remains controversial due to lack of matched controls. We aim to highlight to what extent is neuropathology determined by SARS‐CoV‐2 or by pre‐existing conditions. Findings of 9 Coronavirus disease 2019 (COVID‐19) cases and 6 matched non‐COVID controls (mean age 79 y/o) were compared. Brains were analyzed through immunohistochemistry to detect SARS‐CoV‐2, lymphocytes, astrocytes, endothelium, and microglia. A semi‐quantitative scoring was applied to grade microglial activation. Thal‐Braak stages and the presence of small vessel disease were determined in all cases. COVID‐19 cases had a relatively short clinical course (0–32 days; mean: 10 days), and did not undergo mechanical ventilation. Five patients with neurocognitive disorder had delirium . All COVID‐19 cases showed non‐SARS‐CoV‐2‐specific changes including hypoxic‐agonal alterations, and a variable degree of neurodegeneration and/or pre‐existent SVD. The neuroinflammatory picture was dominated by ameboid CD68 positive microglia, while only scant lymphocytic presence and very few traces of SARS‐CoV‐2 were detected. Microglial activation in the brainstem was significantly greater in COVID‐19 cases ( p = 0.046). Instead, microglial hyperactivation in the frontal cortex and hippocampus was clearly associated to AD pathology ( p = 0.001), regardless of the SARS‐CoV‐2 infection. In COVID‐19 cases complicated by delirium (all with neurocognitive disorders), there was a significant enhancement of microglia in the hippocampus ( p = 0.048). Although higher in cases with both Alzheimer's pathology and COVID‐19, cortical neuroinflammation is not related to COVID‐19 per se but mostly to pre‐existing neurodegeneration. COVID‐19 brains seem to manifest a boosting of innate immunity with microglial reinforcement, and adaptive immunity suppression with low number of brain lymphocytes probably related to systemic lymphopenia. Thus, no neuropathological evidence of SARS‐CoV‐2‐specific encephalitis is detectable. The microglial hyperactivation in the brainstem, and in the hippocampus of COVID‐19 patients with delirium, appears as a specific topographical phenomenon, and probably represents the neuropathological basis of the "COVID‐19 encephalopathic syndrome" in the elderly. Abstract : The neuropathological alterations strictly attributable to SARS‐CoV‐2 infection are overall modest, predominantly caused by innate immunity activation, without evidence of SARS‐CoV‐2‐specific encephalitis. All COVID‐19 cases presented remarkable activation of ameboid CD68‐positive microglia, forming perivascular infiltrates and parenchymal nodules, mostly in the brainstem. Although higher in cases with both Alzheimer's pathology and COVID‐19, cortical neuroinflammation is not related to COVID‐19 per se but mostly to pre‐existing neurodegeneration. Cases with dementia appear more prone to a strong microglial response causing delirium .